Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Matrix metalloproteinase-2 (MMP-2) fluorometric drug discovery kit, RED

 
BML-AK302-0001 96 wells 500.00 USD
 

Product Specification

Alternative Name:Gelatinase A, 72 kDa Type IV collagenase
 
Application:Designed to screen MMP-2 inhibitors using a quenched fluorogenic peptide.
 
Handling:Avoid freeze/thaw cycles.
 
Long Term Storage:-80°C
 
Kit/Set Contains:1 vial MMP-2 enzyme
1 vial substrate (OmniMMP™ RED)
1 vial 6'-TAMRA calibration standard
1 vial control inhibitor (NNGH)
1 bottle (20 ml) assay buffer
1 black 96-well microplate
Instructions
 
 
Miscellaneous/General:Matrix metalloproteinase-2 (MMP-2, gelatinase A, 72kDa type IV collagenase) is a member of the MMP family of extracellular proteases. These enzymes play a role in many normal and disease states by virtue of their broad substrate specificities. Targets of MMP-2 include native and denatured collagens, fibronectin, elastin, laminin-5, pro-TNF-α, and neurocan. MMP-2 is secreted as a 72kDa proenzyme (as measured by SDS-PAGE), and activated by cleavage to 62 and 59kDa. MMP-2 is an important target for inhibitor screening due to its involvement in diseases such as atherosclerosis, and cancer growth, angiogenesis, and metastasis.
 
The MMP-2 Fluorometric (also known as fluorimetric) Drug Discovery Kit, RED is a complete assay system designed to screen MMP-2 inhibitors using a quenched fluorogenic substrate OmniMMP™ RED: TQ3-GABA-Pro-Cha-Abu-Smc-His-Ala-Dab(6-TAMRA)-Ala-Lys-NH2 [TQ3=quencher; GABA=4-aminobutyric acid; Cha=L-cyclohexylalanine; Abu=2-aminobutyric acid; Smc=S-methyl-L-cysteine; Dab=2,4-diaminobutyric acid; 6-TAMRA=6-tetramethylrhodamine]. TAMRA fluorescence is thoroughly quenched by the TQ3 group until cleavage by MMPs separates the two moieties.
 
The OmniMMP™ RED substrate offers key advantages over other MMP substrates. 1) Emission at the red end of the spectrum (576 nm after excitation at 545 nm) avoids the interference at lower wavelengths often exhibited by screening compounds, and by substances commonly found in biological samples and tissue culture medium. 2) MMP substrate peptides display poor aqueous solubility, often with Kms near their limits of solubility, making enzyme and inhibitor kinetics difficult. MMP Kms for OmniMMP™ RED substrate are below its solubility limit. 3) In addition to the efficient binding as exhibited by low Kms, OmniMMP™ RED is avidly cleaved by MMPs, with kcat/Kms in the range of 104-106 M-1sec-1. 4) The ultra-strong fluorescence of OmniMMP™ RED allows for substrate concentrations much lower than the Km, a condition generally desirable in inhibitor screening assays.
 
The assays are performed in a convenient 96-well microplate format. The kit is useful to screen inhibitors of MMP-2, a potential therapeutic target. The compound NNGH is also included as a prototypic control inhibitor.
 
Background / Technical Information:NCBI Reference Sequence: NM_004530
The OmniMMP™ RED substrate offers key advantages over other MMP substrates. 1) Emission at the red end of the spectrum (576 nm after excitation at 545 nm) avoids the interference at lower wavelengths often exhibited by screening compounds, and by substances commonly found in biological samples and tissue culture medium. 2) MMP substrate peptides display poor aqueous solubility, often with Kms near their limits of solubility, making enzyme and inhibitor kinetics difficult.  MMP Kms for OmniMMP™ RED substrate are below its solubility limit. 3) In addition to the efficient binding as exhibited by low Kms, OmniMMP™ RED is avidly cleaved by MMPs, with kcat/Kms in the range of 104-106 M-1sec-1. 4) The ultra-strong fluorescence of OmniMMP™ RED allows for substrate concentrations much lower than the Km, a condition generally desirable in inhibitor screening assays.
 

General Literature References

Matrix metalloproteinases: regulators of the tumor microenvironment: K. Kessenbrock & Z. Werb; Cell 141, 52 (2010), Abstract;
Updated biological roles for matrix metalloproteinases and new "intracellular" substrates revealed by degradomics : G.S. Butler & C.M. Overall; Biochemistry 48, 10830 (2009), Abstract;
Determination of protease cleavage site motifs using mixture-based oriented peptide libraries: B.E. Turk et al.; Nat. Biotechnol. 19, 661 (2001), Abstract;
Matrix metalloproteinases: they're not just for matrix anymore!: L.J. McCawley & L.M. Matrisian; Curr. Opin. Cell Biol. 13, 534 (2001),
Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis: S.J. George; Expert Opin. Investig. Drugs 9, 993 (2000), Abstract;
Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits: L.J. MacPherson, et al.; J. Med. Chem. 40, 2525 (1997), Abstract;
Induction of cell migration by matric metalloproteinase -2 cleavage of laminin-5: G. Giannelli, et al.; Science 277, 225 (1997), Abstract;
The hemopexin-like domain (C domain) of human gelatinase A (matrix metalloproteinase-2) requires Ca2+ for fibronectin and heparin binding. Binding properties of recombinant gelatinase A C domain to extracellular matrix and basement membrane components: U.M. Wallon & C.M. Overall; J. Biol. Chem. 272, 7473 (1997), Abstract; Full Text
Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes: S.J. Atkinson et al.; J. Biol. Chem. 270, 30479 (1995), Abstract; Full Text

Product Toolbox

PRODUCT RESOURCES

Print as PDF
MSDS
Certificate of Analysis
Manual

RELATED PRODUCTS

By catalog section:
By biological activity:
MMP Activity kit

PRODUCT SUPPORT

Technical Service
Bulk Quantity Quote
Customer Service

Related Literature

Product Flyers
Integrated Solutions for Stem Cell Discovery
Integrated Solutions for Stem Cell Discovery 05-Jun-13
Download as PDF

Product Flyers
Accelerate Innovation in Personal Care Products
Accelerate Innovation in Personal Care Products 24-May-12
Download as PDF

All new literature pieces

Recommend this page

 
Keep in touch

©2014 Enzo Life Sciences, Inc.,